SENS
ACHAT TOTAL: 13 953,284 titres (~125 300,49 $ US)
- Insiders
- ROEDER DOUGLAS A
- Total bought
- $125,300
- Total sold
- —
- Last activity
- 2026-08-19
- Last synced
-
2026-08-25 17:08:49
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-22
Despite a compelling insider cluster buy of ~14M shares post-earnings with raised 2026 guidance (~120% revenue growth), SENS's severely distressed fundamentals — persistent negative operating margins, extreme cash burn…
The first sentence of the analysis written for SENS on 2026-08-22 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 44.7% | 2.4% | 13.8% | 16.6% | -5.9% | |
| Ebit Margin | -182.0% | -312.3% | -220.1% | -418.7% | -2089.6% | |
| Ebitda Margin | -177.7% | -305.7% | -214.4% | 987.3% | -2080.5% | |
| Operating Profit Margin | -193.8% | -333.0% | -337.7% | -418.7% | -418.1% | |
| Pretax Profit Margin | -196.0% | -349.8% | -269.7% | 867.2% | -2211.9% | |
| Continuous Operations Profit Margin | -196.0% | -349.8% | -269.7% | 867.2% | -2211.9% | |
| Net Profit Margin | -196.0% | -349.8% | -269.7% | 867.2% | -2211.9% | |
| Bottom Line Profit Margin | -196.0% | -349.8% | -269.7% | -409.7% | -2211.9% | |
| Current Ratio | 4.827 | 2.354 | 7.535 | 5.122 | 7.851 | |
| Quick Ratio | 4.552 | 2.240 | 7.026 | 4.890 | 7.508 | |
| Solvency Ratio | -1.036 | -0.659 | -0.577 | 0.794 | -0.784 | |
| Cash Ratio | 1.665 | 1.920 | 4.387 | 1.137 | 1.819 | |
| Price To Earnings Ratio | -3.325 | -4.188 | -5.182 | 3.394 | -3.708 | |
| Price To Earnings Growth Ratio | 0.099 | -0.307 | 0.038 | -0.024 | 0.571 | |
| Forward Price To Earnings Growth Ratio | 0.099 | -0.307 | 0.038 | -0.024 | 0.571 | |
| Price To Earnings Diluted Ratio | -3.325 | -4.188 | -5.182 | -9.493 | -3.708 | |
| Price To Earnings Diluted Growth Ratio | 0.099 | -0.307 | -3.748 | 0.112 | 0.571 | |
| Price To Book Ratio | 3.773 | -19.913 | 9.044 | -187.108 | -6.078 | |
| Price To Sales Ratio | 6.533 | 14.670 | 14.459 | 29.409 | 82.457 | |
| Price To Free Cash Flow Ratio | -3.823 | -5.257 | -4.591 | -7.234 | -20.033 | |
| Price To Operating Cash Flow Ratio | -3.896 | -5.452 | -4.614 | -7.269 | -20.108 | |
| Debt To Assets Ratio | 0.328 | 0.608 | 0.346 | 0.424 | 0.323 | |
| Debt To Equity Ratio | 0.678 | -3.688 | 1.335 | -29.261 | -0.346 | |
| Debt To Capital Ratio | 0.404 | 1.372 | 0.572 | 1.035 | -0.529 | |
| Long Term Debt To Capital Ratio | 0.368 | 1.912 | 0.535 | 1.048 | -0.476 | |
| Financial Leverage Ratio | 2.068 | -6.067 | 3.861 | -68.972 | -1.072 | |
| Working Capital Turnover Ratio | 0.484 | 0.272 | 0.185 | 0.128 | 0.196 | |
| Operating Cash Flow Ratio | -2.428 | -1.556 | -4.066 | -2.107 | -3.049 | |
| Operating Cash Flow Sales Ratio | -1.677 | -2.691 | -3.134 | -4.046 | -4.101 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.019 | 1.037 | 1.005 | 1.005 | 1.004 | |
| Debt Service Coverage Ratio | -11.502 | -2.404 | -4.321 | 4.720 | -14.482 | |
| Interest Coverage Ratio | -13.803 | -8.871 | -6.805 | -3.669 | -3.420 | |
| Short Term Operating Cash Flow Coverage Ratio | -119.212 | -3.003 | 0.000 | -4.256 | -19.165 | |
| Operating Cash Flow Coverage Ratio | -1.429 | -0.990 | -1.469 | -0.880 | -0.873 | |
| Capital Expenditure Coverage Ratio | -52.983 | -27.005 | -200.466 | -212.538 | -267.038 | |
| Dividend Paid And Capex Coverage Ratio | -52.983 | -27.005 | -200.466 | -212.538 | -267.038 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -3.690 | -4.601 | -6.162 | 3.223 | -4.071 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 44.7% | ▲42.3% | ▲30.4% |
| Ebit Margin | -182.0% | ▲130.3% | ▲462.6% |
| Ebitda Margin | -177.7% | ▲128.0% | ▲180.5% |
| Operating Profit Margin | -193.8% | ▲139.2% | ▲146.5% |
| Pretax Profit Margin | -196.0% | ▲153.8% | ▲236.0% |
| Continuous Operations Profit Margin | -196.0% | ▲153.8% | ▲236.0% |
| Net Profit Margin | -196.0% | ▲153.8% | ▲236.0% |
| Bottom Line Profit Margin | -196.0% | ▲153.8% | ▲491.4% |
| Current Ratio | 4.827 | ▲2.474 | ▼-0.711 |
| Quick Ratio | 4.552 | ▲2.312 | ▼-0.691 |
| Solvency Ratio | -1.036 | ▼-0.377 | ▼-0.584 |
| Cash Ratio | 1.665 | ▼-0.255 | ▼-0.520 |
| Price To Earnings Ratio | -3.325 | ▲0.863 | ▼-0.723 |
| Price To Earnings Growth Ratio | 0.099 | ▲0.406 | ▲0.024 |
| Forward Price To Earnings Growth Ratio | 0.099 | ▲0.406 | ▲0.024 |
| Price To Earnings Diluted Ratio | -3.325 | ▲0.863 | ▲1.854 |
| Price To Earnings Diluted Growth Ratio | 0.099 | ▲0.406 | ▲0.754 |
| Price To Book Ratio | 3.773 | ▲23.686 | ▲43.830 |
| Price To Sales Ratio | 6.533 | ▼-8.137 | ▼-22.973 |
| Price To Free Cash Flow Ratio | -3.823 | ▲1.434 | ▲4.364 |
| Price To Operating Cash Flow Ratio | -3.896 | ▲1.556 | ▲4.372 |
| Debt To Assets Ratio | 0.328 | ▼-0.280 | ▼-0.078 |
| Debt To Equity Ratio | 0.678 | ▲4.366 | ▲6.934 |
| Debt To Capital Ratio | 0.404 | ▼-0.968 | ▼-0.167 |
| Long Term Debt To Capital Ratio | 0.368 | ▼-1.544 | ▼-0.309 |
| Financial Leverage Ratio | 2.068 | ▲8.135 | ▲16.105 |
| Working Capital Turnover Ratio | 0.484 | ▲0.212 | ▲0.231 |
| Operating Cash Flow Ratio | -2.429 | ▼-0.872 | ▲0.213 |
| Operating Cash Flow Sales Ratio | -1.677 | ▲1.014 | ▲1.453 |
| Free Cash Flow Operating Cash Flow Ratio | 1.019 | ▼-0.018 | ▲0.005 |
| Debt Service Coverage Ratio | -11.502 | ▼-9.097 | ▼-5.904 |
| Interest Coverage Ratio | -13.803 | ▼-4.932 | ▼-6.489 |
| Short Term Operating Cash Flow Coverage Ratio | -119.212 | ▼-116.209 | ▼-90.085 |
| Operating Cash Flow Coverage Ratio | -1.429 | ▼-0.439 | ▼-0.301 |
| Capital Expenditure Coverage Ratio | -52.983 | ▼-25.978 | ▲99.023 |
| Dividend Paid And Capex Coverage Ratio | -52.983 | ▼-25.978 | ▲99.023 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -3.690 | ▲0.911 | ▼-0.629 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $230.3M | $329.7M | $323.7M | $482.0M | $1.13B | |
| Enterprise value | $231.2M | $316.1M | $295.8M | $521.6M | $1.16B | |
| EV / Sales | 6.56x | 14.07x | 13.21x | 31.82x | 84.70x | |
| EV / Op. cash flow | -3.91x | -5.23x | -4.22x | -7.87x | -20.66x | |
| EV / Free cash flow | -3.84x | -5.04x | -4.20x | -7.83x | -20.58x | |
| EV / EBITDA | -3.69x | -4.60x | -6.16x | 3.22x | -4.07x | |
| Net debt / EBITDA | -0.01x | 0.20x | 0.58x | 0.24x | -0.11x | |
| Current ratio | 4.83x | 2.35x | 7.54x | 5.12x | 7.85x | |
| Income quality | 0.86x | 0.77x | 1.16x | -0.47x | 0.18x | |
| Graham net-net | $1 | -$1 | $1 | -$1 | -$12 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 107.7% | 112.0% | 122.5% | -207.1% | 105.9% | |
| Working capital | $93.2M | $52.6M | $112.8M | $129.7M | $126.0M | |
| Invested capital | $98.2M | $56.7M | $114.0M | $130.8M | $127.3M | |
| Return on assets | -54.7% | -78.3% | -43.7% | 80.0% | -152.1% | |
| Operating ROA | -60.3% | -62.7% | -47.9% | -36.4% | -48.7% | |
| Return on tangible assets | -55.1% | -78.7% | -43.7% | 80.0% | -152.1% | |
| Return on equity | -113.2% | 474.9% | -168.7% | -5517.0% | 163.0% | |
| Return on invested capital | -66.7% | -91.1% | -62.3% | -42.2% | -31.0% | |
| Return on capital employed | -67.0% | -121.5% | -62.5% | -46.9% | -31.7% | |
| Earnings yield | -30.0% | -23.8% | -18.7% | 29.5% | -26.8% | |
| Free cash flow yield | -26.2% | -19.0% | -21.8% | -13.8% | -5.0% | |
| Capex / Op. cash flow | -1.9% | -3.7% | -0.5% | -0.5% | -0.4% | |
| Capex / Depreciation | 1226.4% | 151.8% | 27.4% | 31.7% | 16.9% | |
| Capex / Sales | 3.2% | 10.0% | 1.6% | 1.9% | 1.5% | |
| SG&A / Sales | 148.9% | 152.3% | 133.7% | 193.0% | 213.2% | |
| R&D / Sales | 89.6% | 183.1% | 217.7% | 242.4% | 199.0% | |
| Stock comp / Sales | 28.8% | 41.1% | 38.7% | 52.6% | 66.0% | |
| Intangibles / Total assets | 0.6% | 0.5% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 129d | 131d | 108d | 62d | 64d | |
| Days payables outstanding | 76d | 53d | 86d | 11d | 30d | |
| Operating cycle | 254d | 205d | 274d | 257d | 224d | |
| Cash conversion cycle | 178d | 151d | 187d | 246d | 193d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-30.1%EV / Sales ▼-53.4%EV / EBITDA ▲+19.8%EV / Op. cash flow ▲+1.319Earnings yield ▼-0.062
Profitability
Return on equity ▼-5.881Return on assets ▲+0.235Return on invested capital ▲+0.244Return on capital employed ▲+0.545Operating ROA ▲+0.024Income quality ▲+0.086Tax burden 0.000
Efficiency
Days sales outstanding ▼-2.540Days payables outstanding ▲+22.678Operating cycle ▲+49.412Cash conversion cycle ▲+26.734Capex / Sales ▼-0.068R&D / Sales ▼-0.935
Balance-sheet strength
Current ratio ▲+2.474Net debt / EBITDA ▼-0.210Working capital ▲+40596000.000Invested capital ▲+41522000.000Intangibles / Total assets ▲+0.002
Change over 5 years
Valuation
Market cap ▼-79.6%EV / Sales ▼-92.3%EV / EBITDA ▲+9.4%EV / Op. cash flow ▲+16.747Earnings yield ▼-0.032
Profitability
Return on equity ▼-2.762Return on assets ▲+0.973Return on invested capital ▼-0.357Return on capital employed ▼-0.354Operating ROA ▼-0.116Income quality ▲+0.670Tax burden 0.000
Efficiency
Days sales outstanding ▲+64.197Days payables outstanding ▲+45.663Operating cycle ▲+30.559Cash conversion cycle ▼-15.104Capex / Sales ▲+0.016R&D / Sales ▼-1.094
Balance-sheet strength
Current ratio ▼-3.024Net debt / EBITDA ▲+0.095Working capital ▼-32834000.000Invested capital ▼-29142000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-07 Senseonics Holdings, Inc. Common Stock Q2 Earnings Call Highlights Senseonics Holdings, Inc. Common Stock NASDAQ: SENS raised its full-year 2026 revenue and gross-margin outlook after reporting second-quarter revenue growth of approximately 120% and its highest organic gross margin to date.
- 2026-08-07 Senseonics Holdings, Inc. (SENS) Q2 2026 Earnings Call Transcript Senseonics Holdings, Inc. (SENS) Q2 2026 Earnings Call Transcript
- 2026-08-06 Senseonics Holdings (SENS) Reports Q2 Loss, Tops Revenue Estimates Senseonics Holdings (SENS) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.4 per share a year ago.
- 2026-07-21 Senseonics Holdings, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call for August 6, 2026 at 4:30 P.M. Eastern Time GERMANTOWN, Md., July 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, August 6, 2026.
- 2026-06-29 Strength Seen in Senseonics (SENS): Can Its 6.1% Jump Turn into More Strength? Senseonics (SENS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 2026-06-11 Senseonics Expands Eversense 365 Ecosystem With Welldoc Partnership SENS partners with Welldoc on a next-gen Eversense 365 app, adding Apple Health/Google Health Connect integration ahead of the U.S. launch.
- 2026-06-06 Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM''s differentiated approach and high performance
- 2026-06-06 Senseonics Holdings, Inc. (SENS) Shareholder/Analyst Call Transcript Senseonics Holdings, Inc. (SENS) Shareholder/Analyst Call Transcript
- 2026-06-01 Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026 GERMANTOWN, Md., June 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today highlights two key company events during the 86th Scientific Sessions of the American Diabetes Association (ADA), taking place June 5-8 in New Orleans, Louisiana.